Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by edroseon Feb 20, 2022 9:41pm
289 Views
Post# 34447148

It’s very obvious they paid mister laurin who owned patents

It’s very obvious they paid mister laurin who owned patents Re 1402 which is parent molecule of 4050 
and as others mentioned salp which is also owned by Thomson had ip/assets as collateral for their loan  they had to pay this back 
when they wiped out retail investors in April 2019 they left 10 million loan that had collaterals 

any potential buyer like boehringer would want these issues resolved 

They want to make us believe that 4050 is worthless if that's true why bother paying laurin etc
<< Previous
Bullboard Posts
Next >>